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Multi‑layered proteogenomic 
analysis unravels cancer metastasis 
directed by MMP‑2 and focal 
adhesion kinase signaling
Yumi Kwon1,2, Seong‑Jun Park1,10, Binh Thanh Nguyen3,4, Mi Jeong Kim1, Sejin Oh5,6, 
Hwanho Lee6,7, Narae Park1,8, Hyun Seok Kim5,6, Min‑Jung Kang3,4, Byung Soh Min9, 
Jin‑Won Lee2, Eun Gyeong Yang1* & Cheolju Lee1,4,8*
The role of matrix metalloproteinase‑2 (MMP‑2) in tumor cell migration has been widely studied, 
however, the characteristics and effects of MMP‑2 in clinical sample of metastatic colorectal cancer 
(CRC) remain poorly understood. Here, in order to unveil the perturbed proteomic signal during 
MMP‑2 induced cancer progression, we analyzed plasma proteome of CRC patients according to 
disease progression, HCT116 cancer secretome upon MMP‑2 knockdown, and publicly available CRC 
tissue proteome data. Collectively, the integrative analysis of multi‑layered proteomes revealed that 
a protein cluster containing EMT (Epithelial‑to‑Mesenchymal Transition)‑associated proteins such as 
CD9‑integrin as well as MMP‑2. The proteins of the cluster were regulated by MMP‑2 perturbation and 
exhibited significantly increased expressions in tissue and plasma as disease progressed from TNM 
(Tumor, Node, and Metastasis) stage I to II. Furthermore, we also identified a plausible association 
between MMP‑2 up‑regulation and activation of focal adhesion kinase signaling in the proteogenomic 
analysis of CRC patient tissues. Based on these comparative and integrative analyses, we suggest that 
the high invasiveness in the metastatic CRC resulted from increased secretion of MMP‑2 and CD9‑
integrin complex mediated by FAK signaling activation.
Colorectal cancer (CRC) is one of the most commonly diagnosed cancers and the third leading cause of cancer-
related deaths worldwide. There are currently few treatment options for advanced and metastatic  patients1. 
Although most primary CRC tumors can be resected surgically, CRC frequently spreads to other organs through 
metastasis and leads to high  mortality2. Cancer metastasis is defined as a detachment of cancer cells from the 
primary tumor and subsequent infiltration to another part of the body. It is an irreversible and largely incurable 
stage of cancer progression and one of the leading causes of cancer  death3. During the initial stage of metastasis, 
remodeling and path-clearing processes of the surrounding extracellular matrix (ECM) are  activated4,5. Matrix 
metalloproteinase-2 (MMP-2), a zinc dependent endopeptidase, is one of the most important enzymes that par-
ticipate in ECM organization and cell migration. A number of studies have found that elevated levels of MMP-2 
determines the invasive and metastatic capacity of tumor  cells6–8. In CRC, increased MMP-2 is also a key feature 
of highly metastatic  tumors4,5,9–11. During invasion and metastasis, tumor cells not only secrete ECM degradative 
enzymes such as MMP-2, but also produce and secrete growth factors, cytokines, and hormones to entice host 
or neighboring cells into producing proteolytic enzymes to degrade the  ECM12–14.
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The secretome encompasses the total set of proteins that are actively transported to the outside of cells. It 
reflects the various pathological or physiological conditions of the  cell15 and reflects pathological conditions 
such as cancer stage and metastasis in  plasma16. As elevated level of MMP-2 promotes tumor progression and 
metastatic ability, the secretory proteins regulated by MMP-2 also could reflect the pathological status of cancer 
cell and be secreted to plasma proteome of CRC patients. However, the secreted proteins controlled by the genetic 
perturbation occurring during tumorigenesis or tumor migration are difficult to study in clinical samples from 
CRC patients due to genetic and physiological heterogeneity. Alternatively, the impact of altered expression 
of MMP-2 on the secreted proteins can be studied in a model system such as cancer cell lines. However, since 
almost all available CRC cell lines are obtained from malignant tumors, they do not represent proper models 
to investigate tumorigenesis according to phased cancer progression. Moreover, conditioned media harvested 
from cultured cells in vitro does not completely mimic that of patients’ blood samples, which contain secretory 
proteins from not only tumor cells, but also normal cells such as stromal cells or liver tissue. Thus, a secretome 
prepared in vitro can only provide an extremely simplified model compared with what actually occurs in vivo17. 
In spite of the significant advances in mass spectrometry, which enables an in-depth proteomic analysis of the 
 secretome15, such an approach based only on cell lines may fail to validate results obtained from clinical samples.
To narrow this gap between studies of cultured conditioned medium and clinical material, we sought to 
integrate quantitative proteomics data from multiple sources: in vitro cultured cell line secretome and proteomes 
obtained from CRC patients; our own experimental data and proteomic data obtainable from public databases. 
We constructed an MMP2 knockdown (KD) cell line, identified differentially secreted proteins, and integrated 
this secretome data into clinical proteomics data. By comparing quantitative information perturbed by MMP2 
KD and the proteomic expressional change according to tumor, node, and metastasis (TNM) stage, we suggest 
that increased metastatic feature of CRC during progression from stage I to II is the result of focal adhesion 
kinase (FAK) activation. Our understanding is also validated in this study in individual CRC proteogenomics 
data by various bioinformatic analysis.
Results
Plasma proteome profiling for differentiating the tumor stage of CRC . We first profiled the 
plasma proteins of CRC patients at different cancer stages as described in Fig. S1A. The classification of TNM 
stages of CRC patients was confirmed histologically and plasma samples representing the same TNM stage (I 
to IV) were each combined separately (Fig. S1B). The four different samples were then analyzed by label-free 
quantification (LFQ) proteomics after top12 abundant plasma proteins were depleted. A total of 1111 proteins 
were identified at 1% false discovery rate (FDR), 70% of which were identified in all samples with an average 
of 936 per sample (Table S1). Using the LFQ intensity, we classified plasma proteins based on their quantitative 
trend according to TNM stage. Unsupervised hierarchical clustering of the 1111 plasma proteins, after z-score 
normalization of the log2 LFQ intensities, resulted in 11 clusters (Fig. 1A). Figure 1A shows the average expres-
sion profile of each plasma proteome cluster (hereafter referred to as “plasma cluster”) according to TNM stage 
and the number of proteins belonging to the cluster. The plasma clusters were applied to the Fisher’s exact test 
to calculate functional enrichment of proteins belonging to each cluster as compared to all the proteins identi-
fied (Fig. 1B). Plasma cluster 10, which has the largest number of proteins, is related to the blood microparticle 
and extracellular region. Plasma cluster 11, which has the second-largest number of proteins, was enriched 
with keratin filament. Plasma cluster 6 containing proteins with radical protein increase from stage I to II was 
enriched with proteins of cell-substrate junction, focal adhesion, and adherens junction. As all the three terms 
enriched in plasma cluster 6 are associated to cell-to-cell adhesion complexes, we focused on this cluster and 
performed further bioinformatic analysis. Gene Set Enrichment Analysis (GSEA) on plasma cluster 6 using 
the hallmark gene sets from the Molecular Signatures Database (MSigDB)18 revealed the gene set “Epithelial 
and mesenchymal transition” significantly (p-value <  10–5, Fig. 1C). Epithelial and mesenchymal transition is a 
highly conserved cellular program that promotes metastasis. In the protein interaction network generated with 
plasma cluster 6, interactions were observed between 41 protein nodes, and MMP-2 was one of the key proteins 
connecting the largest number of proteins (Fig. S2). In our previous study, the expression level of MMP-2 was 
3.03-fold higher in microsatellite stable type CRC tissues compared to matched normal  tissues19. Consistent with 
our current result, it has also been reported that the highest MMP-2 activity is usually measured in stage II of 
CRC 20,21. Therefore, we hypothesized that MMP-2 enhances the migration ability of CRC and a key modulator 
of tumor progression from cancer stage I to II.
MMP2 knock down impairs the migration ability of HCT116 CRC cells. To evaluate the functional 
role of MMP-2 in CRC, we next investigated the effect of MMP-2 on migration ability of tumor in vitro cancer 
cell line. To this end, we initially designed a cell line that could serve as a model for highly metastatic CRC. 
HCT116, a human colon cancer cell line, has been shown to be invasive and highly motile in in vitro  studies22. 
A stable cell line with attenuated MMP-2 activity was established by using an MMP2 specific shRNA plasmid. A 
control cell line was also generated using a vector containing scrambled shRNA. There was no significant change 
in cell proliferation rate between the two cell lines (Fig. S3A). Quantitative PCR analysis confirmed that MMP2 
mRNA levels were 3.5-fold lower in the MMP2 KD cells compared with the control cells (Fig. S3B). Decreased 
MMP-2 protein expression and proteolytic activity were also confirmed by western blot analysis and gelatin 
zymography, respectively (Fig. S3C-D). Cell migration ability, as measured by the area of migration, was signifi-
cantly decreased in MMP2 KD cells when compared with control cells (Fig. 2A,B). MMP-2 modulation of the 
tumor microenvironment has been studied  extensively23. Together with our data, we hypothesized that MMP-2 
also enhances the migration ability of CRC tumor cells by modulating the composition of the secretome.
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Differentially secreted proteins altered by MMP‑2 are highly related to cell motility. In order 
to comprehensively characterize the proteins secreted into conditioned media, we performed a SILAC-based 
quantitative analysis on the secretome of both control (scramble-shRNA) and MMP2 KD (MMP2-shRNA) cell 
lines as shown in Fig. 2C. We prepared three biological replicates from cells independently cultured with for-
ward SILAC (Arg-0/Lys-0: light media for control and Arg-10  [13C6, 15N4]/Lys-8  [13C6, 15N2]: heavy media for 
MMP2 KD) and three additional biological replicates cultured with reverse SILAC (light media for MMP2 KD 
and heavy media for control) (Fig.  S4A). Before sample preparation, near complete incorporation of SILAC 
amino acids into cellular proteins was confirmed (Fig. S4B). Conditioned media were harvested after serum free 
starvation for 24 h. Under these conditions, the cytoskeleton protein α-tubulin was scarcely detectable, implying 
negligible contamination of cytosolic proteins caused by cell death (Fig. S4C). As a result, we identified a total of 
3196 human proteins including 99 FBS-derived bovine proteins and 13 ambiguous proteins, in which the origin 
could not be explicitly. Among the 3196 human proteins, 2596 (81%) were quantifiable; 1972 in at least three sets 
from SILAC analysis and 1278 in all six sets (Table S2).
The quality of our secretome was assessed by Gene Ontology Cellular Compartment (GOCC) enrichment 
analysis for the proteins quantifiable in all six secretome datasets. Significantly enriched GOCC terms, hav-
ing an enrichment factor greater than one in Fisher’s exact test, were all strongly associated with extracellular 
Figure 1.  Plasma proteome analysis of CRC according to cancer stage. (A) Unsupervised hierarchical clustering 
analysis of CRC plasma proteins according to CRC stage was performed with Perseus software. Each of the 4 
points in the graphic trend represents the averaged z-score of the protein expression level at the same CRC stage. 
(B) Fisher’s exact test between the 11 plasma clusters and GOCC value (Benjamini–Hochberg FDR < 0.02). 
Color intensity represents the enrichment factor for the association between the plasma cluster and GOCC 
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Figure 2.  Analysis of differentially secreted proteins in HCT116 cells upon MMP2 KD. (A) Quantification 
of cell migration of HCT116 cells upon MMP2 KD. The error bars represent ± standard deviation (SD) (NS: 
not significant. ***: p < 0.001). (B) Representative fluorescence images of HCT116 cells showing cell migration 
activity at the indicated time after stopper. Dotted circles represent the initial stopper position. Scale bar, 
500 µm. (C) Schematic workflow of the SILAC-based quantitative proteomic analysis of the HCT116 secretome. 
The experiments were performed three times with this setup and three more times with the reverse setup, i.e. 
HCT116 MMP2 KD with light SILAC. (D) Gene ontology enrichment analysis was performed for the proteins 
identified as quantifiable at least three times out of six replicated SILAC experiments compared to all human 
proteins as the background list using Fisher’s exact test (Benjamini–Hochberg FDR < 0.02). (E) Volcano plot for 
the SILAC-quantitation values of the cell secretome. Orange dots indicate proteins with a Benjamini–Hochberg 
FDR < 0.05 and a fold change above ± 1.5. (F) Functional annotation of the differentially secreted proteins by 
using IPA. The blue color represents inactivation of the indicated annotation upon MMP2 KD while the orange 
color represents activation. All quantified proteins were used as the background and Benjamini–Hochberg 
FDR < 0.02 was applied. Box size represents –log (p-value).
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localization. GOCC depleted terms having an enrichment factor < 1 were associated with cytoplasmic localization 
(Fig. 2D). Collectively, the GO analysis strongly indicated that we could exclude the most frequent, technically-
biased identifications that occur due to contamination by FBS proteins and cellular debris.
The quantitation results exhibited a typical normal distribution when log-transformed protein ratios were 
plotted as histograms (Fig. S5) and in a volcano plot (Fig. 2E). By setting a 1.5-fold change as the threshold and 
a p-value < 0.05 for significant up- or down- regulation of the proteins, we identified 164 differentially expressed 
proteins (DEPs). Of those, 142 proteins exhibited down-regulated expression and 22 proteins exhibited up-
regulated expression (Fig. 2E). Gene ontology for molecular function (MF) and biological process (BP) for the 
DEPs was analyzed using Perseus (Table S3). The GOBP gene sets enriched in a Fisher’s exact test were involved 
in “extracellular matrix (or structure) organization,” “cell–cell signaling” and “cell motility.” Likewise, enriched 
GOMF terms were mostly related to peptidase activities. Ingenuity pathway analysis (IPA) was also performed 
on the DEPs to enrich disease-related functional annotations and to predict the direction of activation. The 
analysis indicated “cellular movement,” “cell to cell signaling” and “cell death” as the most enriched annotations 
and these activities were predicted to be suppressed by MMP2 KD (Fig. 2F).
Comparison of cell secretome to plasma proteome profile of cancer patients confirms a con-
sistent regulatory effect of MMP‑2 with disease progression. In order to determine the disease-
association of the secretory proteins that were strongly regulated by MMP-2, we next performed a comparative 
analysis on the two proteomes, secretome and plasma proteome. The HCT116 secretome data contained 523 
matches commonly identified with the plasma proteome (Fig. 3A). As we classified the plasma proteome into 
multiple clusters, we also grouped the secretome into three categories based on the fold change ratio: category 
1 for proteins decreased > 1.5-fold in MMP2 KD; category 2 for proteins with less than 1.5-fold change and cat-
egory 3 for proteins increased > 1.5-fold in MMP2 KD secretion (Fig. 3B). The common proteins between the 
plasma proteome and secretome were evenly populated among the 11 clusters and present in similar proportions 
in each cluster (Table S4). However, if we further classified the proteins into subgroups according to secretome 
categories, non-random associations between the two different proteomes appeared. Fisher’s exact test was per-
formed to determine if there were non-random associations between the plasma clusters and secretome cat-
egories (Fig. 3C). Plasma cluster 6 exhibited a strong association with secretome category 1 with an enrichment 
factor of 2.27 (p = 6.5 ×  10−4). Another significant association was found between plasma cluster 3 and secretome 
category 2 (enrichment factor = 1.23, p = 5.9 ×  10−3). Intriguingly, the plasma cluster 6 contains MMP-2, which 
we specified as the knockdown target through a functional enrichment analysis (Fig. 1B). This suggests that 
there is an increase in the secretion of proteins commonly present in plasma cluster 6 and secretome category 
Figure 3.  Comparative analysis of the cell secretome with the plasma proteome of CRC cancer patients. (A) The 
numbers in the Venn diagram represent those of identified proteins. (B) The HCT116 secretome was divided 
into 3 categories based on  log2(MMP2 KD/Control) ratio. (C) Fisher’s exact test between the three secretome 
categories and 11 plasma clusters (Benjamini–Hochberg FDR < 0.02). Color intensity represents the enrichment 
factor for the association between the secretome and plasma clusters. (D) Z-scored expression profile of MMP-2 
in plasma proteome according to CRC stage. (E) Z-scored expression profiles of proteins in the plasma cluster 6. 
(F) Western blot analysis of the proteins commonly identified in both secretome category 1 and plasma cluster 
6. Protein samples were prepared from the conditioned media (10 µg) of HCT116 Control and HCT116 MMP2 
KD. C Control, D DMSO-only, A ARP-100 treated. Full-length blots are available in supplemental information.
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1 from colon epithelial cells when MMP-2 expression increases (Fig. 3D,E). There were a total of 16 common 
proteins, which may be regulated by or at least associated with MMP-2 (Table 1).
We then performed immunoblotting as an orthogonal validation method (Fig. 3F) to confirm the regula-
tive expression of the 16 proteins identified from the SILAC results. We confirmed that most of the 16 proteins 
exhibited decreased expression in the secretome of the MMP2 KD cell line, and also in the normal secretome 
treated with ARP-100, an MMP-2 specific irreversible inhibitor. Overall, our results suggest that the integra-
tion of multidimensional data from cell lines perturbed at a transcription level, and data from clinical samples 
reflecting similar pathological conditions, can offer better prospects to find a novel signature of cancer etiology.
Comparison of the secretome, plasma proteome, and tissue proteome reveals the CD9‑inte-
grin complex as key molecules for CRC . The next step compared concordance between the plasma 
proteome profile with the tissue proteome profile obtained from CRC patients. For this, we downloaded pub-
licly available data from Clinical Proteomic Tumor Analysis Consortium (CPTAC, NCI/NIH; see Table S5 for 
detailed clinical information) and collected quantitation data for 4,955 proteins. Of these, 2,409 proteins were 
common to that identified in our SILAC secretome data (Fig. 4A). We applied the same clustering strategies to 
this tissue proteome data and performed a comparative analysis between the patient-derived tissue proteome 
and cell line-derived secretome. Unsupervised hierarchical clustering of 4,955 tissue proteomic elements using 
relative expression profiles associated with TNM stage revealed 16 tissue proteomic clusters (hereafter referred 
to as “tissue cluster”, Fig. 4B, Table S6). A cluster named tissue cluster 6 showed a strong association with category 
1 of the secretome as determined by Fisher’s exact test (p-value = 2.7 ×  10−3, enrichment factor = 1.55; Fig. 4C). 
The cluster shared 408 proteins in common with the secretome data. Of these 408 proteins, 31 proteins showed 
decreased expression of more than 1.5-fold when MMP2 was knocked down. Interestingly, we also observed 
MMP-2 in this subgroup. This is consistent with the comparative analysis result between the secretome and the 
plasma proteome as described above. Expression of MMP-2 in the tumor samples increased concomitantly with 
the progression of CRC clinical stage (Fig. 4D). Differences in MMP-2 expression between CRC stages I and II in 
individual tissue proteomes were statistically significant (Figure S6). When we compared the expression profile 
of the plasma cluster 6 (Fig. 3E) and the tissue cluster 6 (Fig. 4E), both showed the most drastic increase in the 
progression from CRC stage I to II.
We found 16 common proteins that were enriched from the comparison of the SILAC secretome to the 
CRC plasma proteome. We also found 31 common proteins that were enriched from the comparison to the 
tissue proteome. In these two comparative analyses, 6 proteins were found in common: CD9, ITGB1, HSPG2, 
CLU, COL18A1, and COL12A1 (Fig. 5A). The surface proteins CD9 and ITGB1 are known to form a com-
plex with  ITGA724 and play a key role in the modulation of integrin-dependent cell migration and adhesion 
 strengthening25. In our data sets, all three components of this complex were found in the same clusters within the 
plasma and tissue proteomes. This finding implies that the components of ITGA7-ITGB1-CD9 complex represent 
similar expression profiles and associated with tumor progression (Fig. 5B,C). Although ITGA7 was not identified 
in our secretome analysis, the expression, or secretory regulation of the complex is likely to be related to MMP-2.
Table 1.  List of the 16 proteins that show decreased secretion by MMP2 KD in CRC cells and increased levels 
in the plasmas of CRC patients during disease progression from stage I to II.
Accession No Protein name Gene name
Plasma (LFQ) Secretome (SILAC)
Z-score
Log2 (MMP2-KD/ control) p-valueCRC I CRC II CRC III CRC IV
P05556 Integrin beta-1 ITGB1 − 0.77 1.46 − 0.54 − 0.15 − 0.97 0.005
P21926 CD9 antigen CD9 − 0.81 1.26 − 0.82 0.37 − 0.70 0.016
Q86SQ4 G-protein coupled receptor 126 GPR126 − 0.72 1.49 − 0.36 − 0.41 − 1.02 0.03
P20827 Ephrin-A1 EFNA1 − 1.06 1.27 − 0.47 0.27 − 1.00 0.016
Q15828 Cystatin-M CST6 − 1.02 1.36 − 0.37 0.03 − 0.97 0.045
P30530 Tyrosine-protein kinase receptor UFO AXL − 1.38 1.02 0.3 0.07 − 0.89 0.039
P22455 Fibroblast growth factor receptor 4 FGFR4 − 0.61 1.46 − 0.7 − 0.17 − 0.80 0.033
P43121 Cell surface glycoprotein MUC18 MCAM − 0.6 1.48 − 0.66 − 0.23 − 0.76 0.005
Q14118 Dystroglycan DAG1 − 0.45 1.5 − 0.4 − 0.66 − 0.66 0.043
P98160 Basement membrane-specific heparan sulfate proteoglycan core protein HSPG2 − 1.03 1.3 0.22 − 0.49 − 0.64 0.049
P10316 HLA class I histocompatibility antigen HLA-A − 1.21 1.16 − 0.32 0.37 − 0.74 0.052
P01034 Cystatin-C CST3 − 1.37 0.92 − 0.1 0.55 − 0.72 0.06
P39060 Collagen alpha-1(XVIII) chain;Endostatin COL18A1 − 0.94 1.41 − 0.4 − 0.08 − 0.74 0.064
O00592 Podocalyxin PODXL − 1.33 1.1 − 0.03 0.26 − 0.62 0.09
P10909 Clusterin CLU − 1.4 0.99 0.24 0.19 − 0.85 0.092
Q99715 Collagen alpha-1(XII) chain COL12A1 − 1.25 1.18 0.21 − 0.14 − 0.60 0.122
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MMP‑2 regulates cell migration via the FAK pathway. The selected findings were further investi-
gated for biological significance. It is well known that activation of FAK signaling involves integrin receptor 
clustering upon binding of cells to ECM  proteins26. The FAK signaling pathway represents a major regulatory 
pathway that receives numerous extracellular stimuli, which are and transmitted intracellularly to control cell 
adhesion and motility (Fig. 6A)26,27. Since we found correlative expression profiles between MMP-2 and the 
CD9-integrin complex in all three kinds of proteome data, we further examined whether the activation of FAK 
signaling was also related to MMP-2 expression level. Furthermore, we also analyzed other proteogenomic data 
(transcriptome and phosphoproteome) of the same CPTAC CRC cohort from which the tissue proteome was 
obtained.
First, we divided the 95 CPTAC CRC patients into two groups based on their expression level of MMP-2 
(Top 50%: MMP-2 high, n = 47; bottom 50%: MMP-2 low, n = 48). GSEA using quantifiable 4,955 tissue proteins 
revealed that KEGG focal adhesion pathway was significantly enriched in the MMP-2 high group (Fig. 6B). 
Among 136 proteins included in the focal adhesion pathway, 83 proteins (61%) showed strong positive correla-
tion with MMP-2 expression level across the patients (Spearman’s rank correlation coefficient > 0, p-value < 0.05).
We also evaluated that FAK signaling event at mRNA expression level. It has been well known that there 
are several transcription factors (TFs) are induced by  FAK26. FAK induces cell cycle progression and apoptosis 
inhibition through transcriptional regulation by KLF8, ETS, JUN, NFκB and YBX1 (Fig. 6A). As a way of show-
ing induction of transcription factors, we calculated activation score of TFs. The activation score of TFs was 
calculated based on the transcriptional abundance of their known target  genes28. As a result, the activation scores 
of TFs except YBX1 were positively correlated with the protein expression level of MMP-2 (Fig. 6C, Spearman’s 
rank correlation coefficient > 0, p-value < 0.05).
When integrin receptor clustering bind to extracellular matrix (ECM), it activates FAK and the activated 
FAK induces downstream pathway mediated through phosphorylation  cascade26,27. Therefore, we would like to 
find an evidence at the phosphoproteome level related to FAK activation. Kinase substrate enrichment analysis 
(KSEA) on the phosphoproteome of MMP-2 high group against MMP-2 low group identified multiple kinases 
such as SRC, JNK and mTOR, which are known to be associated in FAK signaling pathway and to be activated 
in tumors (Fig. 6D).
To further investigate the regulation of FAK signaling upon MMP-2 expression in HCT-116 CRC cell line, 
we measured the phosphorylation status of FAK, ERK, PI3K, and JNK by western blot analysis. Phosphorylation 
Figure 4.  Comparative analysis of the cell secretome with the tissue proteome of CRC cancer patients. (A) 
Schematic workflow of tissue proteome analysis. The tissue proteomic data were obtained from a public data 
repository shared by CPTAC. The numbers in the Venn diagram represent overlap between identified proteins 
from the HCT116 secretome and the tissue proteome. (B) Unsupervised hierarchical cluster analysis of CRC 
tissue proteins according to CRC stage. (C) Fisher’s exact test between the three secretome categories and 16 
tissue clusters (Benjamini–Hochberg FDR < 0.02). The color intensity represents the enrichment factor of the 
association between the secretome and tissue clusters. (D) Z-scored expression profile of MMP-2 in the tissue 
proteome relative to CRC stage. (E) Z-scored expression profiles of the proteins in the tissue cluster 6.
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levels of these FAK signaling proteins were all decreased when cells were treated with 100 µM of ARP-100, an 
MMP-2 inhibitor (Fig. 6E,F). Protein levels also decreased, though not as their much as phosphorylation levels.
Discussion
In this study, we applied a bioinformatics approach to assemble proteomic data from multiple CRC sources 
and establish consensus observations between proteome changes resulting from clinical differences to genetic 
perturbation. For this, we searched for proteins not only with differential secretion patterns according to altered 
expression of MMP-2 in HCT116 CRC cells, but also showing different levels in the plasma and tissue of CRC 
patients relative to cancer stage. The rationale of this strategy was that proteins associated with MMP-2 could 
be key mediators of CRC metastasis. In human cancer, tumor cells are not the dominant contributor of MMP-2 
secretion to the ECM. Stromal cells and infiltrated immune cells also secrete MMP-229–31. Irrespective of its origin, 
MMP-2 degrades the ECM and thus induces remodeling of the matrix and subsequent migration of the tumor 
 cell32. Since MMP-2 is highly expressed in cancer cells, we opted to suppress MMP-2 instead of overexpressing it 
in HCT116 cells to create a less invasive cell. In fact, blocking MMP-2 translation led to decreased cell migration 
and perturbed the secretome, which was associated with cell migration and ECM organization as determined by 
gene ontology analysis. This finding is consistent with that of several previous studies in which MMP-2 amplified 
the motility of cancer  cells13,14. Moreover, the molecular function of both increasing and decreasing proteins was 
primarily peptidase activity. This suggests that MMP-2 modulates the tumor microenvironment by itself and by 
regulating various proteases and  peptidases23,33–35.
In order to connect the information obtained from different analyses, we classified proteins in each proteome 
dataset by expression pattern according to cancer stage, and then search for protein groups in which specific 
proteins were repeatedly found. Interestingly, the only one such protein group included MMP-2 and showed a 
similar expressional pattern to MMP-2. This suggests that a phenomenon found in clinical samples from CRC 
patients can be recapitulated by modulating MMP-2 expression and activity in a cell line. It is intuitive that an 
in vitro study, which may be readily controlled, does not accurately reflect the in vivo environment. Thus, experi-
mental results from the laboratory do not always applicable to the clinic. However, we showed that a comparative 
study at the proteomic level between in vitro genetically perturbed cells and clinical samples may be effective 
at narrowing this gap. The proteins included in both the plasma and tissue clusters that had a high correlation 
with the perturbed secretome, showed a dramatic increase as the disease progressed from stage I to II. It has 
been reported that the highest MMP-2 activity is usually measured in stage II of CRC 20,21. In the clinic, cancer 
progression is determined by a staging system, which reflects the extent, or metastasis at the time of diagnosis. 
Figure 5.  Overview of the proteins highly correlated with MMP-2 perturbation and disease progression. 
(A) The multi-layered proteome analysis result is presented as a Venn diagram depicting overlap between 
the secretome category 1, plasma cluster 6, and the tissue cluster 6. (B,C) Expression profile of the ITGA7-
ITGB1-CD9 complex in plasma (B) and tissue (C) of CRC patients relative to cancer progression.
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The current system for CRC staging is the TNM system, which is based on the size or extent of the primary tumor 
and whether the tumor cell has migrated to nearby lymph nodes or other organs. Stage II CRC is particularly 
distinguishable from stage I according to whether the tumor has spread through the muscle layer of the colon 
wall to the  serosa1,36. Our results suggest that robust mobility is required for tumor cells to penetrate the muscle 
layers. Thus MMP-2 plays a major role for such invasiveness in CRC during progression from stage I to II.
Among the proteins revealed by the comparative analysis, we focused on the CD9-ITGB1-ITGA7 complex. 
As we described in Fig. 6A this complex has been known to initiate FAK signaling by transmitting signals 
 intracellularly25,27. The cytosolic protein FAK can interact directly with the integrin cytoplasmic tail, thereby 
allowing integrins to link to the actin cytoskeleton and promote downstream  signaling37. CD9 also interacts with 
the phosphorylated form of FAK (Tyr397), a modification stimulated by integrin  clustering38. CD9 is a member 
of the tetraspanin superfamily, which is characterized by an ability to associate with various transmembrane 
proteins forming tetraspanin-enriched  microdomains39. Previous reports have shown that tetraspanin CD9 can 
either promote or suppress cancer cell migration and metastasis, depending on the type of interacting partner, 
cancer type, cell type, or the migratory  signal40–45. Other studies have shown that CD9 expression affects MMP-2 
secretion in various disease  models46–48, and MMP-2 secretion increases as a result of FAK signaling  activation49.
We observed significant downregulation of CD9 and ITGB1 in the secretome of MMP-2 suppressed cells. These 
proteins showed a similar expressional trend as MMP-2 in both plasma and tissue proteomes according to CRC 
stage. Although the third component of the complex, ITGA7 was not identified in the cell secretome, it was 
found in the same plasma and tissue clusters where the other two components were found. Thus, it is likely that 
the CD9-ITGB1-ITGA7 complex as a whole play a role in cancer progression.
We have conducted extensive study of MMP-2 and FAK signaling pathway in the context of proteogenom-
ics data from CPTAC CRC 50. It is observed that, in CRC patient, FAK signaling would be more active as the 
expression level of MMP-2 increased. Based on transcriptome level, TFs known to be activated by FAK, showed 
higher transcriptional activity in MMP-2-high groups as measured based on transcriptome level of downstream 
targets. Moreover, at proteome level, FAK signaling pathway was more activated in the MMP-2 high-group 
than in the MMP-2 low group as abundance of most proteins associated in FAK signaling showed significantly 
positive correlation with the abundance of MMP-2 across the CRC patients. It is plausible that activation of 
FAK signaling also increased the MMP-2 expression as FAK also activates the SRC-ERK signaling, and ERK 
induces the expression of MMP-226,51,52. FAK has kinase functions and transfers signals from extracellular space 
to nucleus via phosphorylation mediated signal  cascade53, however, phosphopeptides of the direct substrate 
of FAK were detected only in a few samples of CPTAC cohort, making it difficult to determine the statistically 
significant level of phosphorylation. Nevertheless, based on phosphorylation status of indirect substrate of FAK 
signaling pathway, multiple kinase including SRC, mTOR and JNK exhibited the increased kinase activity score 
in MMP-2 high group.
Our western blot experiment further indicated that secretion of the complex depends on the protease activity 
of MMP-2, because treatment with a catalytic inhibitor exhibited a similar effect to genetic suppression. This 
demonstrates that MMP-2 activates FAK signaling in an activity-dependent manner. We observed an inhibi-
tion of MMP-2 activity and a reduction in FAK autophosphorylation (p-FAK-tyr397), an essential indicator of 
the integrin mediated FAK signaling  activation54. We also observed that proteins such as ERK, PI3K, and JNK 
in the downstream FAK signaling cascade were also inactivated. FAK pathway is located at the central hub in 
various signaling pathways, controls cell motility by activating transcription factors of related  genes55–57. It has 
been reported that the activated FAK causes epithelial-mesenchymal transition (EMT) in cancer metastasis in 
colorectal cancer cells and thereby enhancing the invasion and metastasis of colorectal  cancer58. Therefore, these 
results support a hypothesis that increased MMP-2 activity enhances cellular motility by forming a positive 
feedback loop with the CD9-integrin complex and FAK signaling pathway.
In summary, we identified MMP-2 regulatory proteins by collecting concordant evidence between the 
secretome of HCT116 colon cancer cells, the CRC patient plasma, and tissue proteomes. The biological func-
tion of those proteins showed significant correlation in such comparative analysis and was highly associated with 
cell migratory ability. Their expression level also increased sharply when CRC progressed from stage I to II. We 
demonstrated that high invasiveness, featured in CRC cells with increased secretion of MMP-2, is the result of 
MMP-2 activation of FAK signaling through the CD9-integrin complex. Consequently, this induces a positive 
feedback of MMP-2 upregulation. The experimental approach performed here will provide a new strategy for the 
discovery of diagnostic and prognostic markers, which may increase the relative success of translational research.
Materials and methods
Plasma proteome analysis. Preparation of plasma samples. The plasma samples used in this study were 
collected from 187 CRC patients who had been recruited by the Yonsei Severance hospital (Seoul, Korea) for our 
previous  study59. All participating patients were full informed and informed consent was obtained from each 
patient. Authorization to use these samples for research was obtained from the Institutional Review Board of 
the Yonsei Severance hospital. For all blood preparation, 3 mL of blood was collected in an EDTA tube, and the 
plasma was prepared as suggested by Human Proteome Organization Plasma Proteome  Project60. The number 
of CRC patient donors in TNM stages I, II, III, and IV were 48, 48, 64, and 27, respectively. The plasma samples 
were combined according to TNM stage. The pooled plasma samples were then mixed with a protease inhibitor 
cocktail (complete Mini EDTA-free, Roche), aliquoted and immediately frozen at − 80 °C. All experiments per-
formed in this study were carried out in accordance with the approved guidelines and regulations.
Depletion of high abundance proteins. An affinity-based depletion spin column (Thermo Scientific Pierce) was 
used for single-step removal of twelve high abundance proteins. These top twelve abundant proteins were albu-
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min, transferrin, fibrinogen, α1-antitrypsin, haptoglobin, α1-acid glycoprotein, α2-macroglobulin, apolipopro-
tein A-I, apolipoprotein A-II, IgA, IgG, and IgM. Pooled plasma (10 µL) was loaded directly to the resin slurry in 
a spin column. A total of 40 µL of each plasma sample from each group was depleted. The mixture in the column 
was incubated with end-over-end mixing for 1 h at RT. After incubation, the unbound fraction was collected 
and concentrated by ultrafiltration using Amicon Ultra-0.5 Centrifugal filters (3 kDa cutoff; Millipore, MA), 
exchanged to a buffer containing 8 M urea, 75 mM NaCl and 50 mM Tris–HCl (pH 8.2)61. Protein concentra-
tions were determined using a bicinchoninic acid assay kit (Thermo scientific, Rockford, IL).
Digestion of plasma proteins. The depleted plasma samples (150 µg) were reduced with 5 mM TCEP at 25 °C for 
1 h and alkylated with 15 mM iodoacetamide at 25 °C for 1 h in the dark. The samples were diluted tenfold with 
50 mM Tris–HCl (pH 8.2) and treated with mass spectrometry grade mixed trypsin/Lys-C (Promega, Madison, 
WI) at 37 °C for 16 h. The ratio of enzyme to protein was 1:25 (w/w). The digest was desalted using a C18 mac-
rospin spin column (Harvard Apparatus, MA, USA), vacuum-dried and stored at − 20 °C until use.
Basic pH reversed‑phase liquid chromatography. Peptides were fractionated by basic pH reversed-phase liquid 
chromatography using an Agilent 1290 Infinity LC System (Agilent Technologies). The chromatography was 
performed on an XBridge BEH130 C18 column (4.6  μm i.d. × 250  mm length; pore size 130  Å and particle 
size 3.5 μm; Waters Corporation, Milford, MA, USA) at a flow rate of 0.5 mL/min62. For mobile phase, 10 mM 
ammonium formate (pH 10) was set as channel A and 10 mM ammonium formate (pH 10) in 90% acetonitrile 
(pH 10) as channel B. The peptides were dissolved in 125 μL of mobile phase A and then injected into a 100 μL 
sample loop. Gradient setup was 2–5% B for 10 min, 5–40% B for 40 min, 40–70% B for 15 min, holding 70% 
B for 10 min, and finally 70–5% for 15 min. Fractionation was done by collecting 96 tubes (1 tube/0.8 min) 
throughout running. The resultant 96 fractions were pooled to 12 concatenated fractions by the following rule. 
A set of an arithmetic sequence with a common difference of 12 was pooled into one concatenated fraction, for 
instance, number 1, 13, 25, 37, 49, 51, 63 and 75 fractions were pooled into the first concatenated faction. The 
fractions were vacuum-dried and stored at –20 °C until MS analysis.
Liquid chromatography and tandem mass spectrometry (LC–MS/MS). LC–MS/MS was performed, as previ-
ously  described63. Peptides were reconstituted in 0.4% acetic acid and analyzed on a reversed-phase C18 column 
(20 cm × 75 μm i.d., 3 μm, 120 Å, packed in-house; Dr. Maisch) using an Eksigent nanoLC-ultra 1D plus system 
at a flow rate of 300 nL/min. Before use, the column was equilibrated with 95% buffer A (0.1% formic acid in 
 H2O) and 5% buffer B (0.1% formic acid in acetonitrile). The peptides were eluted with a linear gradient from 
5 to 50% buffer B over 186 min followed by 80% B wash for 10 min and aqueous re-equilibration at a flow rate 
of 300 nL/min with a total run time of 230 min. A Q Exactive quadrupole-orbitrap hybrid mass spectrometer 
(Thermo Scientific, Bremen, Germany) was used in DDA mode. Survey full-scan MS spectra (m/z 350–1800) 
were acquired with a resolution of 70,000. Source ionization parameters were as follows: spray voltage, 2.5 kV; 
capillary temperature, 300 °C; and s-lens level, 44.0. The MS peak width at half height was < 30 s. The MS/MS 
spectra of the 12 most intense ions from the MS1 scan with a charge state ≥ 2 were acquired with the following 
options: resolution, 17,500; isolation width, 2.0 m/z; normalized collision energy, 27%; ion selection threshold, 
4.00E ± 03 counts; and peptide match, ‘preferred’.
Secretome analysis. Construction of MMP‑2‑suppressed cells and stable isotopic labeling with amino acids 
in cell culture (SILAC). A stable HCT116 cell line with suppressed MMP-2 expression was constructed by 
transfecting a pGIPZ lentiviral vector harboring an shRNA sequence for MMP2. The shRNA was designed as 
 described64. Another shRNA with a scrambled sequence was designed for use as a negative control. Transfec-
tion with the indicated shRNA vector was performed using the X-tremeGENE™ HP DNA transfection reagent 
(Roche, Basel, Switzerland) according to manufacturer’s instructions. For antibiotic selection, the transfected 
cells were grown in RPMI 1640 media with 6 µg/mL puromycin (Sigma-Aldrich). After construction of the sta-
ble cell lines, decreased expression of MMP2 gene was confirmed by quantitative RT-PCR.
Figure 6.  Regulation of FAK signaling by MMP-2 activity. (A) The focal adhesion kinase pathway. FAK 
activated by integrin-CD9 complex increases cell motility and cell survival. (B) GSEA of CPTAC CRC patients 
showed that focal adhesion pathway is associated with the MMP-2 high group (MMP-2 protein expression is 
higher than median level). Heat map represents the relative protein abundance of 136 genes associated in focal 
adhesion pathway. Correlation test was performed between the expressions of MMP-2 and each of 136 genes. 
83 proteins show significant and positive correlations to MMP-2 expression (Spearman’s correlation coefficients 
(rho) > 0, p-value < 0.05). (C) Correlation between MMP-2 and transcriptional factors in FAK signaling pathway 
in the CPTAC CRC data. Heatmaps for MMP-2 represents protein abundance. Heatmaps for ETS1, JUN, KLF8, 
NFKB1 and YBX1 represent transcription factor activity scores. Bar charts on the right represent Spearman 
correlation coefficients (rho). *P < 0.05, **P < 0.01; Spearman correlation test. (D) Evaluation of kinase activity 
by KSEA in MMP-2 high group and MMP-2 low group. Asterisks indicate the kinases associated in FAK 
signaling pathway. (E) Phosphorylation of FAK, ERK, PI3K, JNK were measured by western blot analysis with 
corresponding phospho-site-specific antibodies. Protein samples were prepared from the cell lysate of each 
condition and 25 µg of proteins were separated on SDS-PAGE. Full-length blots are available in supplemental 
information. (F) The phosphorylation level was determined by normalized phospho-band intensity of each 
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The established cells were cultured in SILAC RPMI media (RPMI-1640 media deficient in L-lysine and 
L-arginine; Thermo Scientific, San Jose, CA) supplemented with 10% dialyzed fetal bovine serum (FBS) (dialyzed 
by ultrafiltration, Sigma-Aldrich), 1 × penicillin/streptomycin (Gibco, Rockville, MD), 253.7 µg/mL L-Arg and 
55.2 µg/mL L-Lys. For preparation of heavy SILAC medium, [L-13C6, 15N4]-Arg and [L-13C6, 15N2]-Lys (Arg10 and 
Lys8, respectively; Cambridge isotope) were used instead of the conventional amino acids (Arg0; Lys0) used for 
light SILAC. Cells were grown for at least six doublings. SILAC amino acids were incorporated into more than 
95% of the cellular proteome as determined by mass spectrometry (MS). Excess amount of arginine in media may 
get metabolized by cells to proline leading to reduced quantitative accuracy. This metabolic conversion can be 
largely prevented by the addition of L-proline to the SILAC culture  medium65. However, in this study, we didn’t 
add proline in advance and arginine-to-proline conversion was found to be 11.51%.
Collection of conditioned media. Grown cells were transferred to an appropriate serum free SILAC medium. 
After a 24-h incubation, the conditioned medium was harvested, cleared of floating cells and debris by centrifu-
gation (400 g, 10 min, 4 °C) followed by filtration (0.22 µm, Millipore, MA). After addition of 50 mM EDTA and 
1 mM PMSF to prevent proteolytic degradation, the conditioned medium was concentrated by ultrafiltration 
using Amicon Ultra-15 centrifugal filter devices (10 kDa cutoff, Millipore, MA). Buffer was exchanged to 8 M 
urea, 50 mM Tris (pH 8.2), 75 mM NaCl during the repeated concentration steps. Meanwhile, whole cell lysates 
were prepared from the cells that remained in the culture dishes. Cells were harvested in the buffer described 
above and then lysed by sonication. The lysate was centrifuged (12,000 g, 10 min) and the supernatants were 
collected for further analysis. Protein concentration was determined by a bicinchoninic acid assay (Thermo 
scientific, Rockford, IL). All protein samples were stored at − 80 °C until use.
Tryptic digestion and pre‑fractionation. The secretomes (50 µg each) from light and heavy SILAC conditions 
were pooled. The pooled sample was reduced with 10 mM dithiothreitol at 37 °C for 25 min and alkylated with 
15 mM iodoacetamide at 25 °C for 30 min. Then, the sample was diluted by eightfold to decrease urea concen-
tration to at least 1 M and digested with sequencing-grade modified trypsin (Promega, Madison, WI) at 1:25 
(w/w) enzyme to protein ratio at 37 °C for 16 h. The tryptic digest was separated based on isoelectric point using 
an OFFGEL electrophoresis fractionator (Agilent Technology, Santa Clara, CA) as  described59. The fractionated 
peptides were collected into 12 fractions, desalted with  C18 macrospin spin columns (Harvard Apparatus, MA), 
vacuum-dried (miVac Duo concentrator, Genevac, Suffolk, UK) and stored at − 20 °C until MS analysis.
Liquid chromatography and tandem mass spectrometry. LC–MS/MS was performed, as previously  described66. 
Peptides were reconstituted in 0.4% acetic acid and analyzed on a reversed-phase C18 column (20 cm × 75 μm 
i.d., 3 μm, 300 Å, packed in-house; Dr. Maisch GmbH) using an Eksigent MDLC system at a flow rate of 300 
nL/min. Before use, the column was equilibrated with 95% mobile phase A (0.1% formic acid in  H2O) and 5% 
mobile phase B (0.1% formic acid in ACN). The peptides were eluted with a linear gradient from 5–40%B over 
90 min followed by an 80%B wash and re-equilibration with 5%B at a flow rate of 300 nL/min with a total run 
time of 120 min. The HPLC system was connected to an LTQ Orbitrap XL mass spectrometer (Thermo Scien-
tific, Bremen, Germany) operated in DDA mode. Survey full-scan MS spectra (m/z 300–2000) were acquired in 
the Orbitrap with a resolution of 100,000. Source ionization parameters were as follows: spray voltage, 1.9 kV; 
capillary temperature, 275 °C. The MS/MS spectra of the 10 most intense ions from the MS1 scan, with a charge 
state ≥ 2, were acquired in the ion-trap using the following parameters: isolation width, 2.0 m/z; normalized col-
lision energy, 35%; dynamic exclusion, 30 s.
Protein identification and quantitation. Raw data files were processed using MaxQuant (ver.1.5.8.2) 
software with the Andromeda search  engine67. The MS/MS spectra were searched against the UniProt human 
database (released in Jan. 2016). With respect to the secretome, sequences for 199 experimentally validated FBS 
proteins (common Repository of FBS proteins) were added to the human database to reduce false-positives orig-
inating from FBS  contamination66,68. The following search parameters were used: full tryptic specificity allowing 
N-terminal cleavage to proline, up to two missed cleavage sites, carbamidomethylation of cysteine residues set 
as a fixed modification, methionine oxidation and N-terminal protein acetylation as variable modifications. The 
false discovery rate (FDR) was set to 0.01 for proteins and peptides and was determined by searching a reverse 
database. Maximal allowed precursor mass deviation for peptide identification was 4.5 ppm and maximal frag-
ment mass deviation was 20 ppm. For quantification of SILAC-labeled secretome, multiplicity was set as two to 
match the number of SILAC labels used (i.e. light and heavy) with Arg10 + Lys8 set as heavy. Relative abundance 
was measured based on the ratio of MS1 resolved peak areas of the isotopic clusters for the SILAC pairs. For 
quantification of plasma proteome, label-free quantification (LFQ) was performed with a minimum ratio count 
of  two69.
The MS raw files are available via  PRIDE70 partner repository with the dataset identifier PXD018304.
Bioinformatics. Ingenuity Pathway Analysis (IPA, Qiagen, http:// www. ingen uity. com) was used to deter-
mine knowledgebase-oriented protein networks and to generate a heat map presenting the functional annota-
tion related to disease. Perseus (version 1.5.8.4)71 was used for all other bioinformatic analyses performed in this 
study.
We utilized the colon tissue proteomic data generated and published by the Clinical Proteomic Tumor Analy-
sis Consortium (NCI/NIH) (https:// cptac- data- portal. georg etown. edu/ cptac/s/ S037). In this Clinical Proteomic 
Tumor Analysis Consortium (CPTAC) Cancer proteome confirmatory colon  study50, 104 colon tumor samples 
were analyzed by two proteome characterization centers, Vanderbilt University and Pacific Northwest National 
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Laboratory. One hundred tumors were investigated by label-free global proteomic profiling and 95 tumors were 
analyzed by TMT10-plex labeling quantification. We used the latter TMT10-plex data because the TMT platform 
usually provides greater precision in quantification than the label-free  platform50. Other data such as clinical 
information were also provided by the same CPTAC data portal.
Gene set enrichment analysis (GSEA) was performed for pathway enrichment analysis of CPTAC CRC tis-
sue  data72. Tumor samples grouped according to the expression level of MMP-2; Top 50% (n = 47), MMP-2 high 
group and bottom 50% (n = 48), MMP-2 low group. KEGG pathway was used for enrichment analysis and the 
statistical significance was evaluated based on the multiple testing correction with the false discovery rate < 0.25. 
The heat map was generated using the  Morpheus73.
For hierarchical clustering and generation of heat maps of plasma proteome and tissue proteome, we used 
the built-in tool in Perseus (version 1.5.8.4)71. All quantified proteins were Z-scored normalized across the stage 
and clustered based on Euclidean distance. The number of clusters for plasma proteome (11 clusters) and tissue 
proteome (16 clusters) were defined based on distance threshold for 1.578.
For scoring activities of FAK-associated transcriptional factors, gene expression data of the same CPTAC CRC 
cohort from which the tissue proteome was downloaded from the NCI-GDC portal (https:// portal. gdc. cancer. 
gov/) using the TCGA biolinks package (version 2.17.1)74. As per standard practice, gene expression data were 
log2-transformed after 1 was added to each gene expression value. Transcriptional interaction data between five 
transcription factors (TFs) activated by FAK (FAK-TFs: ETS1, JUN, KLF8, NFκB1, and YBX1)26 and their target 
genes were acquired from the TF-target interaction database available in  OmniPath28, excluding data derived 
from computational prediction. A target gene enrichment score for each of the FAK-TFs was calculated by using 
single sample Gene Set Enrichment  Analysis75 on gene expression data and presented as a heat map using the 
ComplexHeatmap package (version 3.11)76.
Western blot analysis. Equal amounts of protein from each sample were separated on SDS-PAGE gels 
and transferred to PVDF membranes (Bio-Rad, Hercules, CA). The membranes were blocked with 5% skim 
milk in TBST buffer (20 mM Tris, 137 mM NaCl, and 0.1% Tween 20, pH 7.4) for 30 min at RT and incubated 
with the appropriate primary antibody overnight at 4 °C. After several washes with TBST, the membranes were 
incubated with the corresponding IgG-HRP secondary antibodies at a dilution of 1:10,000 for 1 h at RT, washed, 
and visualized with the ECL chemiluminescent substrate (Bio-Rad, Hercules, CA). Unedited, expanded western 
blots provided in Supplementary Information. Several western blots were cut prior to antibody hybridization for 
reagent conservation.
In vitro cell proliferation, migration assays. Cell proliferation of the constructed cell lines was evalu-
ated using the MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide)-based colorimetric assay 
(Invitrogen, V13154), according to the manufacturer instructions. Cells were seeded in 96-well plates at 5 ×  103 
cells per well and absorbance was measured using a microplate reader at 540 nm in every 24 h for 4 days.
For measuring migration ability of cells, cells were seeded into Oris™ Cell Migration Assay 96-well plates 
(Tissue Culture Treated) fitted with stoppers (Platypus Technologies, CMA1.101) at a concentration of 5 ×  105 
cells per well. The cells were then incubated for 4 h in a humidity chamber at 37 °C and 5%  CO2. After removal 
of the stopper, the cells were incubated for 16 h. Live cells were stained with 0.5 µg/mL of calcein AM solution 
and incubated at 37 °C for 1 h. Fluorescence images were obtained using a low light microscope system and the 
amount of fluorescence was determined on a BioTek Synergy™ microplate reader using 485 and 528 nm excita-
tion/emission filters at a sensitivity of 55 nm.
Zymography. The proteolytic activity of MMP-2 was measured and visualized using SDS-PAGE zymogra-
phy, in which 0.1% (w/v) porcine gelatin was incorporated into a 10% polyacrylamide gel. Conditioned medium 
containing 5 µg protein (concentrated by ultrafiltration if required) was loaded onto the gel and separated by 
electrophoresis. The gel was washed in distilled water, incubated for 1 h at RT with 2.5% (v/v) Triton X-100 in 
50 mM Tris–Cl (pH 7.5), washed again in distilled water and incubated for 16 h at 37 °C with incubation buffer 
(50 mM Tris–Cl pH 7.5, 10 mM  CaCl2, 0.01%  NaN3, 1 µM  ZnCl2). After a brief wash with distilled water, the gel 
was stained with Coomassie Brilliant Blue. Unstained white bands of digested substrate in the blue background 
indicated metalloproteinase activity.
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